FINWIRES · TerminalLIVE
FINWIRES

Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis

By

Karyopharm Therapeutics (KPTI) said Tuesday that a late-breaking abstract from its phase 3 trial of selinexor combined with ruxolitinib in myelofibrosis was accepted for an oral presentation at the 2026 European Hematology Association Congress in mid-June.

The company said new data will highlight a post-hoc analysis of 24 patients from phase 1 of the trial, which indicates that achieving a spleen volume reduction of 35% or more may predict overall survival, consistent with a similar analysis from the phase 3 trial.

Shares of Karyopharm Therapeutics were down more than 8% in Tuesday trading.

Price: $8.99, Change: $-0.84, Percent Change: -8.50%

Related Articles

Wire

Mastercard Appoints Ling Hai as CFO; Sachin Mehra to Become Chief Business Officer

Mastercard (MA) said Tuesday it has appointed Ling Hai, president of Asia Pacific, Europe, Middle East and Africa, as the company's chief financial officer, effective Aug. 3.He succeeds Sachin Mehra, who will move into a newly created role as chief business officer, responsible for country operations across the globe, Mastercard said.Additionally, President of the Americas Linda Kirkpatrick will become chief services officer, succeeding Craig Vosburg, the firm said, adding that Vosburg will transition to vice chair and serve as a global ambassador for the company.Dimi Dosis, president of Eastern Europe, Middle East and Africa, will become chief commercial payments officer, succeeding Raj Seshadri, who will become a senior strategic advisor to the chief executive officer, Mastercard said.Price: $483.78, Change: $-11.47, Percent Change: -2.32%

$MA
Wire

Life Time Seen Benefiting From High-Income Exposure, RBC Says

Life Time Group (LTH) is well positioned to benefit from its high income member base and room to expand wallet share through in-center services, RBC Capital Markets said in a Tuesday note.Investor interest centered on in-center growth, new club growth, balance sheet leverage and capital allocation, according to the note.RBC said Life Time's median household income rose to $160,000 in 2025 from $119,000 in 2021, supporting what it sees as a favorable backdrop for spending across the membership base.However, RBC analysts said the biggest growth opportunity remains growing wallet share from existing users of in-center services, especially dynamic personal training, which it said accounts for about half of in-center revenue.The research firm also noted new club productivity is improving, with some locations reaching maturity at 24 months, faster than the historical average and site selection becoming more efficient.RBC maintained its outperform rating on Life Time and raised its price target to $43 from $38.Price: $32.33, Change: $+0.99, Percent Change: +3.16%

$LTH
Wire

Abivax Faces Increasing Risk of Black Box Warning for Obefazimod, Wedbush Says

Abivax (ABVX) faces an increasing risk of black box warning for obefazimod due to malignancies reported from a recent trial, Wedbush Securities said in a Tuesday note.The company said Monday that the phase 3 maintenance trial evaluating obefazimod in adults with moderately to severely active ulcerative colitis met its primary endpoint, with both 25 mg and 50 mg doses also achieving all key secondary endpoints.Wedbush noted the seven malignancies reported in the trial's 50 mg cohort and one in the 25 mg, along with the novel proposed mechanism for obefazimod, as signals for an eventual black box warning. The brokerage also flagged this warning's potential negative impact on market share and marketing costs.The possible regulatory and commercial delays could also pressure profitability based on obefazimod's patent life, Wedbush added, while noting obefazimod's potent monotherapy efficacy with a top-line clinical remission rate of 50% for both doses.Wedbush Securities upgraded Abivax to neutral from underperform and cut its price target to $90 from $110.Price: $79.22, Change: $-50.47, Percent Change: -38.92%

$ABVX